Donate

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]

Hormone Therapy (ADT) for Prostate Cancer Patients Might Provide Us Another Long Term Gift – Alzheimer’s Disease

Hormone therapy (ADT) is notorious for providing us with side effects. Some of these side effects are best described as ones that deteriorate our general quality of life. For example the most common one we all are familiar with is, of course, hot flashes. You could also add erectile dysfunction as well as loss of [...]

Pamorelin (Trelstar) Now Available in the Philippines

Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically [...]

Be Cautious Taking Megace To Treat Hormone Therapy Hot Flashes

When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently.  Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is [...]

Short Term Androgen Therapy Might Be Better For More Aggressive Gleason Grade Prostate Cancer

In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

Combination Chemotherapy And ADT In Hormone Sensitive Prostate Cancer Betters Survival and the Quality Of Life

There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]

Intermittent ADT, Does It Increase A Man’s Risk Factors For Serious Side Effects?

Once again we see what seems to be logical isn’t necessarily the way it actually works!  In a surprising study result, it was shown that the use of intermittent androgen-deprivation therapy (IADT) for prostate cancer is not associated with fewer long-term adverse events than continuous ADT!  Who would have guessed? We all thought that intermittent [...]

The Relationship Between ADT and Cardiovascular Evens In German Men

ASCO GU has given us a number of interesting posters, some of which I have already written about in prior posts. Another of these posters (abstract 232)  was about an analysis by Ruessel and colleagues describing cardiovascular events among men with prostate cancer using German claims data. The researchers, in a retrospective study, attempted to [...]

Go to Top